Powder X-ray diffraction method for the quantification of cocrystals in the crystallization mixture

Context: The solid state purity of cocrystals critically affects their performance. Thus, it is important to accurately quantify the purity of cocrystals in the final crystallization product. Objective: The aim of this study was to develop a powder X-ray diffraction (PXRD) quantification method for investigating the purity of cocrystals. The method developed was employed to study the formation of indomethacin-saccharin (IND-SAC) cocrystals by mechanochemical methods. Materials and methods: Pure IND-SAC cocrystals were geometrically mixed with 1:1 w/w mixture of indomethacin/saccharin in various proportions. An accurately measured amount (550 mg) of the mixture was used for the PXRD measurements. The most intense, non-overlapping, characteristic diffraction peak of IND-SAC was used to construct the calibration curve in the range 0–100% (w/w). This calibration model was validated and used to monitor the formation of IND-SAC cocrystals by liquid-assisted grinding (LAG). Results: The IND-SAC cocrystal calibration curve showed excellent linearity (R2 = 0.9996) over the entire concentration range, displaying limit of detection (LOD) and limit of quantification (LOQ) values of 1.23% (w/w) and 3.74% (w/w), respectively. Validation results showed excellent correlations between actual and predicted concentrations of IND-SAC cocrystals (R2 = 0.9981). Discussion: The accuracy and reliability of the PXRD quantification method depend on the methods of sample preparation and handling. The crystallinity of the IND-SAC cocrystals was higher when larger amounts of methanol were used in the LAG method. Conclusion: The PXRD quantification method is suitable and reliable for verifying the purity of cocrystals in the final crystallization product.

[1]  Katsuhiko Yamamoto,et al.  High-throughput cocrystal slurry screening by use of in situ Raman microscopy and multi-well plate. , 2010, International journal of pharmaceutics.

[2]  T. Fukami,et al.  Characterization of multicomponent crystal formed between indomethacin and lidocaine , 2009, Drug development and industrial pharmacy.

[3]  Amjad Alhalaweh,et al.  Bioavailability of indomethacin‐saccharin cocrystals , 2010, The Journal of pharmacy and pharmacology.

[4]  D. Bugay,et al.  Quantitation of cefepime.2HCl dihydrate in cefepime.2HCl monohydrate by diffuse reflectance IR and powder X-ray diffraction techniques. , 1996, Journal of pharmaceutical and biomedical analysis.

[5]  S. Velaga,et al.  Indomethacin–Saccharin Cocrystal: Design, Synthesis and Preliminary Pharmaceutical Characterization , 2008, Pharmaceutical Research.

[6]  William Jones,et al.  Improving Mechanical Properties of Crystalline Solids by Cocrystal Formation: New Compressible Forms of Paracetamol , 2009 .

[7]  J. Tantry,et al.  Processing-induced phase transitions of theophylline--implications on the dissolution of theophylline tablets. , 2007, Journal of pharmaceutical sciences.

[8]  Rumi Faizer,et al.  Quantification of crystallinity in blends of lyophilized and crystalline MK-0591 using x-ray powder diffraction , 1995 .

[9]  S. Velaga,et al.  Hansen solubility parameter as a tool to predict cocrystal formation. , 2011, International journal of pharmaceutics.

[10]  Thomas Rades,et al.  Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  W Press,et al.  Crystalline solids. , 1980, Science.

[12]  N. Rodríguez-Hornedo,et al.  Transformation pathways of cocrystal hydrates when coformer modulates water activity. , 2010, Journal of pharmaceutical sciences.

[13]  A. Shete,et al.  Crystal engineering to improve physicochemical properties of mefloquine hydrochloride , 2010, Drug development and industrial pharmacy.

[14]  Lynne S. Taylor,et al.  Spectroscopic Characterization of Interactions Between PVP and Indomethacin in Amorphous Molecular Dispersions , 1997, Pharmaceutical Research.

[15]  K R Morris,et al.  Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. , 2001, Advanced drug delivery reviews.

[16]  Kwok Chow,et al.  Engineering of pharmaceutical materials: an industrial perspective. , 2008, Journal of pharmaceutical sciences.

[17]  Luis Padrela,et al.  Formation of indomethacin-saccharin cocrystals using supercritical fluid technology. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[18]  P. York Solid-state properties of powders in the formulation and processing of solid dosage forms , 1983 .

[19]  S. Childs,et al.  The role of solvent in mechanochemical and sonochemical cocrystal formation: a solubility-based approach for predicting cocrystallisation outcome , 2009 .

[20]  R. Suryanarayanan,et al.  Quantitation of crystallinity in substantially amorphous pharmaceuticals and study of crystallization kinetics by X-ray powder diffractometry , 2000, Powder Diffraction.

[21]  Orn Almarsson,et al.  Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? , 2003, Chemical communications.

[22]  Aeri Park,et al.  Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API , 2006, Pharmaceutical Research.

[23]  C. Strachan,et al.  Influence of sample characteristics on quantification of carbamazepine hydrate formation by X-ray powder diffraction and Raman spectroscopy. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[24]  Adrian C. Williams,et al.  Quantitative analysis of mannitol polymorphs. X-ray powder diffractometry--exploring preferred orientation effects. , 2002, Journal of Pharmaceutical and Biomedical Analysis.

[25]  Thomas Rades,et al.  Quantitative solid-state analysis of three solid forms of ranitidine hydrochloride in ternary mixtures using Raman spectroscopy and X-ray powder diffraction. , 2009, Journal of pharmaceutical and biomedical analysis.

[26]  P York,et al.  Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. , 2007, Advanced drug delivery reviews.

[27]  A. Bansal,et al.  Quantification of olanzapine polymorphs using powder X-ray diffraction technique. , 2007, Journal of pharmaceutical and biomedical analysis.

[28]  Sarsvatkumar Patel,et al.  Effect of sample preparation method on quantification of polymorphs using PXRD , 2010, Pharmaceutical development and technology.

[29]  Ning Shan,et al.  The role of cocrystals in pharmaceutical science. , 2008, Drug discovery today.

[30]  T. Rades,et al.  Powder diffractometric assay of two polymorphic forms of ranitidine hydrochloride. , 1999, International journal of pharmaceutics.

[31]  P. Schroeder,et al.  Accurate quantification of quartz and other phases by powder X-ray diffractometry , 1997 .

[32]  R. Banerjee,et al.  Variable-temperature powder X-ray diffraction of aromatic carboxylic acid and carboxamide cocrystals. , 2007, Chemistry, an Asian journal.

[33]  K. Steffens,et al.  Quantifying Low Amorphous or Crystalline Amounts of Alpha‐Lactose‐Monohydrate Using X‐Ray Powder Diffraction, Near‐Infrared Spectroscopy, and Differential Scanning Calorimetry , 2004, Drug development and industrial pharmacy.

[34]  Naír Rodríguez-Hornedo,et al.  Solubility Advantage of Pharmaceutical Cocrystals , 2009 .